Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Codexis (CDXS – Research Report) today. The company’s shares closed yesterday at $1.66.
According to TipRanks, Hewitt is an analyst with an average return of -8.5% and a 32.13% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Repligen, Streamline Health Solutions, and Apyx Medical.
Codexis has an analyst consensus of Strong Buy, with a price target consensus of $7.67.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.98 and a one-year low of $1.45. Currently, Codexis has an average volume of 990K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDXS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis (CDXS) Company Description:
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Read More on CDXS:
